Enzalutamide + Bicalutamide + GnRH analog
Phase 2Active 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer
Trial Timeline
Apr 15, 2019 → Sep 15, 2029
NCT ID
NCT03809000About Enzalutamide + Bicalutamide + GnRH analog
Enzalutamide + Bicalutamide + GnRH analog is a phase 2 stage product being developed by Astellas Pharma for Prostate Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03809000. Target conditions include Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Prostate Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03809000 | Phase 2 | Active |
Competing Products
20 competing products in Prostate Cancer